1![1 ANN Newsletter - No. 5 / October 2011 C li ni ca l T r i al s: UPD ATE Exon Skipping 1 ANN Newsletter - No. 5 / October 2011 C li ni ca l T r i al s: UPD ATE Exon Skipping](https://www.pdfsearch.io/img/5f36471b7aa81bdd1a3b6b9221992b20.jpg) | Add to Reading ListSource URL: www.ann.org.auLanguage: English - Date: 2011-10-13 05:16:20
|
---|
2![September 17, 2014 PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) September 17, 2014 PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT)](https://www.pdfsearch.io/img/9dd5be8629d5ebfb394db8d3aeda56d6.jpg) | Add to Reading ListSource URL: hbmpartners.comLanguage: English - Date: 2014-09-18 03:00:04
|
---|
3![Phase 3 Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy: Frequently Asked Questions What is ataluren? Ataluren (formerly called PTC124®) is an investigational new drug, which means it is Phase 3 Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy: Frequently Asked Questions What is ataluren? Ataluren (formerly called PTC124®) is an investigational new drug, which means it is](https://www.pdfsearch.io/img/b2f9b0df85d76d10431f045ce357ade4.jpg) | Add to Reading ListSource URL: muscle.caLanguage: English - Date: 2013-11-30 21:08:11
|
---|
4![PTC Therapeutics Raises $26.6 Million In Private Placement Financing Company Developing Small-Molecule Drugs Targeting Post-Transcriptional Control Mechanisms Has Raised Over $130 Million To Date SOUTH PLAINFIELD, NJ - N PTC Therapeutics Raises $26.6 Million In Private Placement Financing Company Developing Small-Molecule Drugs Targeting Post-Transcriptional Control Mechanisms Has Raised Over $130 Million To Date SOUTH PLAINFIELD, NJ - N](https://www.pdfsearch.io/img/1dd9a94364bc382631a7b34e5a50464a.jpg) | Add to Reading ListSource URL: capital.vulcan.comLanguage: English - Date: 2008-09-12 20:32:06
|
---|
5![Dr. Jack Parent, MD Dr. Lori Isom, PhD Dr. Miriam Meisler, PhD Dr. Jack Parent, MD Dr. Lori Isom, PhD Dr. Miriam Meisler, PhD](https://www.pdfsearch.io/img/4dd7c1be7a6631e8319094d42d63d79a.jpg) | Add to Reading ListSource URL: www.dravetfoundation.orgLanguage: English - Date: 2013-12-03 16:27:27
|
---|
6![Microsoft PowerPoint - TsengCMDcopy Microsoft PowerPoint - TsengCMDcopy](https://www.pdfsearch.io/img/7556e1ebf5a3a22f1a1bf78a2d43c259.jpg) | Add to Reading ListSource URL: www.curecmd.orgLanguage: English - Date: 2010-09-09 13:12:18
|
---|
7![COMMUNIQUE DE PRESSE Vendredi 23 mai 2014 AMM conditionnelle pour l’Ataluren Une première pour un médicament de thérapie innovante pour la myopathie de Duchenne COMMUNIQUE DE PRESSE Vendredi 23 mai 2014 AMM conditionnelle pour l’Ataluren Une première pour un médicament de thérapie innovante pour la myopathie de Duchenne](https://www.pdfsearch.io/img/1151c67d927567a42cf6db4e0dee5358.jpg) | Add to Reading ListSource URL: www.myologie.orgLanguage: French - Date: 2014-05-28 01:46:52
|
---|
8![COMMUNIQUE DE PRESSE Vendredi 23 mai 2014 AMM conditionnelle pour l’Ataluren Une première pour un médicament de thérapie innovante pour la myopathie de Duchenne COMMUNIQUE DE PRESSE Vendredi 23 mai 2014 AMM conditionnelle pour l’Ataluren Une première pour un médicament de thérapie innovante pour la myopathie de Duchenne](https://www.pdfsearch.io/img/e5f6052d87c729eb5a7387b49848b760.jpg) | Add to Reading ListSource URL: www.institut-myologie.orgLanguage: French - Date: 2014-05-28 01:46:52
|
---|